{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-22-000025","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2022-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.460988+00:00","generated_at":"2026-06-21T15:03:27.980598+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Caribou Biosciences receives FDA IND clearance for CB-011, allogeneic anti-BCMA CAR-T therapy for multiple myeloma","bullets":["CB-011 is a genome-edited allogeneic anti-BCMA CAR-T cell therapy with immune cloaking.","CaMMouflage Phase 1 trial is an open-label, multicenter study evaluating CB-011 in relapsed/refractory multiple myeloma.","Patient enrollment at dose level 1 (50x10^6 CAR-T cells) expected to begin in early 2023.","CB-011 uses Cas12a chRDNA edits: anti-BCMA CAR insertion, TRAC KO, and B2M-HLA-E fusion for immune cloaking.","This is Caribou's second allogeneic CAR-T to enter clinic, following CB-010 (anti-CD19, PD-1 KO) in ANTLER trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-22-000025","json":"https://secwatch.observer/filing/0001619856-22-000025.json","markdown":"https://secwatch.observer/filing/0001619856-22-000025.md","text":"https://secwatch.observer/filing/0001619856-22-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985622000025/0001619856-22-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985622000025/crbu-20221121.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T15:03:27.980598+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}